<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7103900/results/search/disease/results.xml">
  <result pre="IntRheumatology International0172-81721437-160XSpringer Berlin HeidelbergBerlin/Heidelberg pmcid: 71039004570 doi: 10.1007/s00296-020-04570-z : Correspondence" exact="Coronavirus disease" post="2019 (COVID-19) and anti-rheumatic drugs http://orcid.org/0000-0002-1652-4648GeorgievTsvetoslavtsetso@medfaculty.org[], grid.460112.0Clinic of Rheumatology,"/>
  <result pre="International0172-81721437-160XSpringer Berlin HeidelbergBerlin/Heidelberg pmcid: 71039004570 doi: 10.1007/s00296-020-04570-z : Correspondence Coronavirus" exact="disease" post="2019 (COVID-19) and anti-rheumatic drugs http://orcid.org/0000-0002-1652-4648GeorgievTsvetoslavtsetso@medfaculty.org[], grid.460112.0Clinic of Rheumatology,"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="as a global pandemic. To the Editor, Current pandemic of" exact="coronavirus disease" post="2019 (COVID-19) is caused by severe acute respiratory syndrome"/>
  <result pre="a global pandemic. To the Editor, Current pandemic of coronavirus" exact="disease" post="2019 (COVID-19) is caused by severe acute respiratory syndrome"/>
  <result pre="pandemic of coronavirus disease 2019 (COVID-19) is caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite drastic containment measures,"/>
  <result pre="of coronavirus disease 2019 (COVID-19) is caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Despite drastic containment measures, the"/>
  <result pre="coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Despite drastic containment measures, the COVID-19"/>
  <result pre="necessitates urgent multidisciplinary strategy to contain the spread of the" exact="disease" post="and prevent its complications. The affection of the lower"/>
  <result pre="the disease and prevent its complications. The affection of the" exact="lower" post="airways in severe COVID-19 is driven by uncontrolled immune-mediated"/>
  <result pre="of the lower airways in severe COVID-19 is driven by" exact="uncontrolled" post="immune-mediated inflammatory response. T lymphocytes are the main target"/>
  <result pre="response. T lymphocytes are the main target cells in severe" exact="acute" post="respiratory syndrome (SARS) due to COVID-19, triggering cytokine storm"/>
  <result pre="T lymphocytes are the main target cells in severe acute" exact="respiratory" post="syndrome (SARS) due to COVID-19, triggering cytokine storm with"/>
  <result pre="lymphocytes are the main target cells in severe acute respiratory" exact="syndrome" post="(SARS) due to COVID-19, triggering cytokine storm with subsequent"/>
  <result pre="response [2, 3]. Importantly, there is no association between the" exact="viral" post="load and severity of the disease [4]. The cascade"/>
  <result pre="no association between the viral load and severity of the" exact="disease" post="[4]. The cascade of the disease pathways is reminiscent"/>
  <result pre="and severity of the disease [4]. The cascade of the" exact="disease" post="pathways is reminiscent of systemic immune disturbances, particularly those"/>
  <result pre="[4]. The cascade of the disease pathways is reminiscent of" exact="systemic" post="immune disturbances, particularly those in severe rheumatic flare. Based"/>
  <result pre="is reminiscent of systemic immune disturbances, particularly those in severe" exact="rheumatic" post="flare. Based on the current knowledge of COVID-19 pathophysiology"/>
  <result pre="brings about hope for developing evidence-based anti-rheumatic therapies for the" exact="viral" post="disease. Systemic corticosteroids (CS) are known to potently dampen"/>
  <result pre="hope for developing evidence-based anti-rheumatic therapies for the viral disease." exact="Systemic" post="corticosteroids (CS) are known to potently dampen immune inflammation."/>
  <result pre="are known to potently dampen immune inflammation. Like in inflammatory" exact="rheumatic" post="diseases, CS might serve as a &quot;bridge&quot; to specific"/>
  <result pre="Health Organization (WHO), however, recommends to avoid routine administration of" exact="systemic" post="CS for the treatment of viral pneumonia outside clinical"/>
  <result pre="avoid routine administration of systemic CS for the treatment of" exact="viral pneumonia" post="outside clinical trials [6]. Chloroquine (CQ) and its less"/>
  <result pre="routine administration of systemic CS for the treatment of viral" exact="pneumonia" post="outside clinical trials [6]. Chloroquine (CQ) and its less"/>
  <result pre="decades, these drugs have been used for the treatment of" exact="systemic" post="lupus erythematosus and rheumatoid arthritis. The justification for their"/>
  <result pre="these drugs have been used for the treatment of systemic" exact="lupus erythematosus" post="and rheumatoid arthritis. The justification for their use in"/>
  <result pre="been used for the treatment of systemic lupus erythematosus and" exact="rheumatoid arthritis." post="The justification for their use in COVID-19 is largely"/>
  <result pre="9]. CQ has proved efficient against the virus in COVID-19" exact="pneumonia" post="in Chinese clinical trials, justifying the inclusion of the"/>
  <result pre="in the Guidelines for the Prevention, Diagnosis, and Treatment of" exact="Pneumonia" post="Caused by COVID-19 [10]. An open-label non-randomized clinical trial"/>
  <result pre="clinical trial by Gauret et al. showed that HCQ reduces" exact="viral" post="load in most COVID-19 patients and that its efficacy"/>
  <result pre="adverse outcomes [13, 14]. IL-6 levels are associated with SARS-CoV-2" exact="viral" post="load [15]. Blocking IL-6 receptor might be a promising"/>
  <result pre="Blocking IL-6 receptor might be a promising strategy in the" exact="disease" post="management. Preliminary evidence from a small uncontrolled trial in"/>
  <result pre="strategy in the disease management. Preliminary evidence from a small" exact="uncontrolled" post="trial in China proves that tocilizumab in addition to"/>
  <result pre="for severe COVID-19 management by the National Institute for the" exact="Infectious" post="Diseases ‘Lazzaro Spallanzani' [5]. The recent advances in the"/>
  <result pre="severe COVID-19 management by the National Institute for the Infectious" exact="Diseases" post="‘Lazzaro Spallanzani' [5]. The recent advances in the understanding"/>
  <result pre="to the similarities of the cytokine storm syndromes in this" exact="viral" post="disease and inflammatory rheumatic disorders, justifying the use of"/>
  <result pre="the similarities of the cytokine storm syndromes in this viral" exact="disease" post="and inflammatory rheumatic disorders, justifying the use of anti-rheumatic"/>
  <result pre="the cytokine storm syndromes in this viral disease and inflammatory" exact="rheumatic" post="disorders, justifying the use of anti-rheumatic drugs in both"/>
  <result pre="conditions. Rheumatologists should share their experience with managing patients with" exact="rheumatic" post="disorders and join the global multidisciplinary fight against COVID-19."/>
  <result pre="no conflict of interest. References References 1.World Health Association (2020)" exact="Coronavirus disease" post="2019 (COVID-19) situation Report—61. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200322-sitrep-62-covid-19.pdf. Accessed 22 Mar 2020"/>
  <result pre="conflict of interest. References References 1.World Health Association (2020) Coronavirus" exact="disease" post="2019 (COVID-19) situation Report—61. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200322-sitrep-62-covid-19.pdf. Accessed 22 Mar 2020"/>
  <result pre="Accessed 22 Mar 2020 2.XuZShiLWangYZhangJHuangLZhangCTaiYPathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med202010.1016/S2213-2600(20)30076-X 3.HuangCWangYLiXRenLZhaoJHuYet al.Clinical features of"/>
  <result pre="22 Mar 2020 2.XuZShiLWangYZhangJHuangLZhangCTaiYPathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med202010.1016/S2213-2600(20)30076-X 3.HuangCWangYLiXRenLZhaoJHuYet al.Clinical features of patients"/>
  <result pre="infected with 2019 novel coronavirus in Wuhan, ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 4.ZouLRuanFHuangMLiangLHuangHHongZet al.SARS-CoV-2" exact="viral" post="load in upper respiratory specimens of infected patientsN Engl"/>
  <result pre="novel coronavirus in Wuhan, ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 4.ZouLRuanFHuangMLiangLHuangHHongZet al.SARS-CoV-2 viral load in" exact="upper" post="respiratory specimens of infected patientsN Engl J Med202010.1056/NEJMc2001737 5.NicastriEPetrosilloNIppolitoGD’OffiziGMarchioniLBartoliTAet"/>
  <result pre="coronavirus in Wuhan, ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 4.ZouLRuanFHuangMLiangLHuangHHongZet al.SARS-CoV-2 viral load in upper" exact="respiratory" post="specimens of infected patientsN Engl J Med202010.1056/NEJMc2001737 5.NicastriEPetrosilloNIppolitoGD’OffiziGMarchioniLBartoliTAet al.National"/>
  <result pre="infected patientsN Engl J Med202010.1056/NEJMc2001737 5.NicastriEPetrosilloNIppolitoGD’OffiziGMarchioniLBartoliTAet al.National Institute for the" exact="Infectious" post="Diseases &quot;L. Spallanzani&quot; IRCCS. Recommendations for COVID-19 clinical managementInfect"/>
  <result pre="patientsN Engl J Med202010.1056/NEJMc2001737 5.NicastriEPetrosilloNIppolitoGD’OffiziGMarchioniLBartoliTAet al.National Institute for the Infectious" exact="Diseases" post="&quot;L. Spallanzani&quot; IRCCS. Recommendations for COVID-19 clinical managementInfect Dis"/>
  <result pre="Dis Rep202010.4081/idr.2020.8543 6.World Health Organization (2020) Clinical management of severe" exact="acute" post="respiratory infection (SARI) when COVID-19 disease is suspected: interim"/>
  <result pre="Rep202010.4081/idr.2020.8543 6.World Health Organization (2020) Clinical management of severe acute" exact="respiratory" post="infection (SARI) when COVID-19 disease is suspected: interim guidance,"/>
  <result pre="6.World Health Organization (2020) Clinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected: interim guidance, 13"/>
  <result pre="Clinical management of severe acute respiratory infection (SARI) when COVID-19" exact="disease" post="is suspected: interim guidance, 13 March 2020. https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf. Accessed"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov20206161410.1038/s41421-020-0156-031934347 8.SchrezenmeierEDörnerTMechanisms of action of hydroxychloroquine and"/>
  <result pre="chloroquine and its hydroxyl analogue to face bacterial, fungal and" exact="viral" post="infections in the 21st centuryInt J Antimicrob Agents20073029730810.1016/j.ijantimicag.2007.05.01517629679 10.GaoJTianZYangXBreakthrough:"/>
  <result pre="and its hydroxyl analogue to face bacterial, fungal and viral" exact="infections" post="in the 21st centuryInt J Antimicrob Agents20073029730810.1016/j.ijantimicag.2007.05.01517629679 10.GaoJTianZYangXBreakthrough: Chloroquine"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends2020141727310.5582/bst.2020.0104732074550 11.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and azithromycin as"/>
  <result pre="consider cytokine storm syndromes and immunosuppressionLancet202010.1016/S0140-6736(20)30628-0 15.ChenXZhaoBQuYChenYXiongJFengYet al.Detectable serum SARS-CoV-2" exact="viral" post="load (RNAaemia) is closely associated with drastically elevated interleukin"/>
 </snippets>
</snippetsTree>
